Cell Signaling Technology

ChIP-Grade Protein G Magnetic Beads

#9006 · $243

100
Citing papers
16.5k
Combined citations
Supplier page Find this product

Research areas

Melanoma and MAPK Pathways15Cell death mechanisms and regulation15Protein Kinase Regulation and GTPase Signaling11Hepatocellular Carcinoma Treatment and Prognosis9Chronic Myeloid Leukemia Treatments8Cytokine Signaling Pathways and Interactions8Cancer Mechanisms and Therapy7Cancer, Hypoxia, and Metabolism7

Papers citing this product

1
Sorafenib Blocks the RAF/MEK/ERK Pathway, Inhibits Tumor Angiogenesis, and Induces Tumor Cell Apoptosis in Hepatocellular Carcinoma Model PLC/PRF/5
Cancer Research·2006·1.5k cit.·DOI
2
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
Cell·2010·1.5k cit.·DOI
3
BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Cancer Research·2008·1.1k cit.·DOI
4
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)
Blood·2009·641 cit.·DOI
5
Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas
Journal of Clinical Oncology·2009·573 cit.·DOI
6
Masitinib (AB1010), a Potent and Selective Tyrosine Kinase Inhibitor Targeting KIT
PLoS ONE·2009·409 cit.·DOI
7
Mutant FLT3: A Direct Target of Sorafenib in Acute Myelogenous Leukemia
JNCI Journal of the National Cancer Institute·2008·338 cit.·DOI
8
Apoptosis Induced by the Kinase Inhibitor BAY 43-9006 in Human Leukemia Cells Involves Down-regulation of Mcl-1 through Inhibition of Translation
Journal of Biological Chemistry·2005·284 cit.·DOI
9
Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models
Cancer Medicine·2018·258 cit.·DOI
10
The B-RafV600E inhibitor dabrafenib selectively inhibits RIP3 and alleviates acetaminophen-induced liver injury
Cell Death and Disease·2014·231 cit.·DOI